Endogenous metal-binding proteins and sites (MBPs)

Endogenous metal-binding proteins and sites represent a broad and essential class of biological molecules that incorporate metal ions—such as zinc, iron, copper, and magnesium—as critical cofactors for their structural integrity and biochemical activity (Source: NCBI, PMC3943830). These proteins, collectively known as the metalloproteome, include a diverse array of enzymes, transport proteins, and transcription factors that govern fundamental processes like cellular respiration, DNA synthesis, and signal transduction (Source: UniProt). In clinical practice, these sites are the primary targets for chelating agents used to treat metal toxicity and hereditary overload disorders, such as Wilson's disease and hemochromatosis (Source: StatPearls, NBK557466). Additionally, many widely used drugs function by binding to metal ions within the active sites of enzymes, such as ACE inhibitors for hypertension and carbonic anhydrase inhibitors for glaucoma (Source: PubChem). Dysregulation of these metal-binding sites is also a hallmark of various pathologies, including neurodegenerative diseases like Alzheimer's and the progression of certain cancers where metal-dependent proteases facilitate metastasis (Source: PubMed, 25611108). Despite their therapeutic importance, targeting these sites is challenging due to the risk of non-specific metal depletion and the potential for disrupting essential physiological pathways (Source: Journal of Biological Inorganic Chemistry).

Other names

MetalloproteinsMetalloenzymesMetal-binding motifsMetalloproteomeEndogenous metal-binding sites

Drugs targeting these sites primarily act through two mechanisms: chelation, where the drug forms a stable complex with a metal ion to facilitate its excretion (e.g., iron or copper removal), and direct inhibition, where a drug binds to a metal ion within a protein's active site to block its biological function (e.g., zinc-dependent enzyme inhibition) (Source: PMC3943830, StatPearls).